Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.47 |
| ▸ | ITGAV | P06756 | 13/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7463010 | 0.88 | ITGAV (0.43) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7471267 | 0.88 | ITGB3 (0.46) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL382408 | 0.85 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL7048410 | 0.81 | ITGB3 (0.57) | ITGB3ITGA2BITGAV | |
| SCHEMBL7459020 | 0.81 | ALDH1A1 (0.38) | ITGB3ITGA2BITGAV | |
| SCHEMBL7462236 | 0.81 | ITGB3 (0.56) | ITGB3ITGA2BITGAV | |
| SCHEMBL7049503 | 0.80 | GRIN3B (0.39) | ITGB3ITGA2BITGAV | |
| SCHEMBL7651260 | 0.79 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL381774 | 0.79 | ITGB3 (0.58) | ITGB3ITGA2BITGAV | |
| SCHEMBL7650186 | 0.78 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | claimed |
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1250935-A1 | REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGA2B 7/4885ITGAV 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.